NCT04575194View on ClinicalTrials.gov

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

May 30, 2023

Conditions
ObesityBlood Pressure
Interventions
DRUG

Liraglutide 6 MG/ML [Saxenda]

3 mg of sc liraglutide daily plus lifestyle intervention

DRUG

Naltrexone-Bupropion Combination

32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention

Trial Locations (1)

11527

RECRUITING

First Department of Propaedeutic Internal Medicine, Athens

Sponsors

Collaborators (1)

Athens Medical Center
All Listed Sponsors
collaborator

Athens Medical Center

OTHER

lead

National and Kapodistrian University of Athens

OTHER

NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy | Biotech Hunter | Biotech Hunter